These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 7834962)
1. Chirality in new drug development. Clinical pharmacokinetic considerations. Nation RL Clin Pharmacokinet; 1994 Oct; 27(4):249-55. PubMed ID: 7834962 [No Abstract] [Full Text] [Related]
2. Drug disposition in three dimensions: an update on stereoselectivity in pharmacokinetics. Brocks DR Biopharm Drug Dispos; 2006 Nov; 27(8):387-406. PubMed ID: 16944450 [TBL] [Abstract][Full Text] [Related]
3. Confounding factors for sex differences in pharmacokinetics and pharmacodynamics: focus on dosing regimen, dosage form, and formulation. Chen ML Clin Pharmacol Ther; 2005 Oct; 78(4):322-9. PubMed ID: 16198651 [No Abstract] [Full Text] [Related]
4. Pediatric drug development: formulation considerations. Ali AA; Charoo NA; Abdallah DB Drug Dev Ind Pharm; 2014 Oct; 40(10):1283-99. PubMed ID: 24483293 [TBL] [Abstract][Full Text] [Related]
5. [Chiral switch: towards a better benefit-risk ratio?]. Blin O Therapie; 2004; 59(6):625-8. PubMed ID: 15789826 [TBL] [Abstract][Full Text] [Related]
6. Lead optimization strategies as part of a drug metabolism environment. Korfmacher WA Curr Opin Drug Discov Devel; 2003 Jul; 6(4):481-5. PubMed ID: 12951811 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic screening strategy for discovery work-use of rodent species: lessons learnt and probing newer thoughts. Srinivas NR Drug Metab Pharmacokinet; 2009; 24(2):197-8. PubMed ID: 19430178 [No Abstract] [Full Text] [Related]
8. Effects of stereochemical aspects on drug interaction in pharmacokinetics. Zhou Q; Yao TW; Zeng S Acta Pharmacol Sin; 2002 May; 23(5):385-92. PubMed ID: 11978187 [TBL] [Abstract][Full Text] [Related]
12. Strategic proposals for avoiding toxic interactions with drugs for clinical use during development and after marketing of a new drug: pharmacokinetic consideration. Sugiyama Y; Iwatsubo T; Ueda K; Ito K J Toxicol Sci; 1996 Dec; 21(5):309-16. PubMed ID: 9035043 [No Abstract] [Full Text] [Related]
13. Pediatric Drug Development and Dosage Form Design. Preis M; Breitkreutz J AAPS PharmSciTech; 2017 Feb; 18(2):239-240. PubMed ID: 28116597 [No Abstract] [Full Text] [Related]
15. [Chirality and drugs]. Testa B; Reist M; Carrupt PA Ann Pharm Fr; 2000 Jul; 58(4):239-46. PubMed ID: 10915971 [TBL] [Abstract][Full Text] [Related]
16. [Age-related changes in pharmacokinetics and pharmacodynamics]. Akishita M Nihon Rinsho; 2013 Nov; 71(11):1888-91. PubMed ID: 24397155 [No Abstract] [Full Text] [Related]
17. Why can't a woman be more like a man? Gray J Clin Pharmacol Ther; 2007 Jul; 82(1):15-7. PubMed ID: 17571069 [TBL] [Abstract][Full Text] [Related]
18. Importance of stereospecific bioanalytical monitoring in drug development. Caldwell J J Chromatogr A; 1996 Jan; 719(1):3-13. PubMed ID: 8589835 [TBL] [Abstract][Full Text] [Related]